US Patent 11382956 Amylin analogues
Patent 11382956 was granted and assigned to Zealand Pharma A/S on July, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 11 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 5 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 29 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
113829560
Date of Patent
July 12, 2022
0Patent Application Number
166641680
Date Filed
October 25, 2019
0Patent Citations
Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Patent Citations
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
113829560
Date of Patent
July 12, 2022
0Patent Application Number
166641680
Date Filed
October 25, 2019
0Patent Citations
Patent Primary Examiner
Edits on 13 Jul, 2022
Golden AI
Edits made to:
Infobox (+10 properties)
Article (+408 characters)
US Patent 11382956 Amylin analogues
Article
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11382956
Date of patent
July 12, 2022
Patent application number
16664168
Date Filed
October 25, 2019
Patent citations
Patent primary examiner
Find more entities like US Patent 11382956 Amylin analogues
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
